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Abstract
Randomized clinical trials are considered the gold standard for estimating causal effects.
Nevertheless, in studies that are aimed at examining adverse effects of interventions, such trials
are often impractical because of ethical and financial considerations. In observational studies,
matching on the generalized propensity scores was proposed as a possible solution to estimate
the treatment effects of multiple interventions. However, the derivation of point and interval
estimates for these matching procedures can become complex with non-continuous or censored
outcomes. We propose a novel Approximate Bayesian Bootstrap algorithm that result in statis-
tically valid point and interval estimates of the treatment effects with categorical outcomes. The
procedure relies on the estimated generalized propensity scores and multiply imputes the unob-
served potential outcomes for each unit. In addition, we describe a corresponding interpretable
sensitivity analysis to examine the unconfoundedness assumption. We apply this approach to
examines the cardiovascular safety of common, real-world anti-diabetic treatment regimens for
Type 2 diabetes mellitus in a large observational database.
Keywords: Causal inference; Generalized propensity score; Multiple imputation, Multiple treat-
ments; Approximate Bayesian Bootstrap.
1 Introduction
1.1 Overview
Cardiovascular disease results in substantial morbidity and is the leading cause of mortality in
type 2 diabetes mellitus. Cardiovascular mortality rates among individuals with type 2 diabetes
are twice the mortality rates of non-diabetic individuals [1]. There is convincing evidence that
blood glucose control in type 2 diabetes reduces the risk of microvascular complications, such as
retinopathy, nephropathy, and neuropathy [2]. Based on available data, it has been noted that
improved glucose control in type 2 diabetes does not necessarily reduce adverse macrovascular
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cardiovascular outcomes, such as myocardial infarction, stroke, and heart failure [3]. Investigation
of the potential beneficial or harmful effects of new glucose-lowering medications on the incidence
of major cardiovascular events via prospective, randomized controlled trials has been mandated by
the FDA as part of their drug approval process starting in 2008 [4]. However, comparable trials for
older anti-diabetic medications are not available, and insights into cardiovascular outcomes from
real-world observational data are limited for both new and older antihyperglycemic medications.
Metformin has been recommended as a first-line agent in type 2 diabetes because of its low
cost, high glucose-lowering efficacy, and low risk of hypoglycemia [5]. There are several classes
of antihyperglycemic therapies with distinct mechanisms of action recommended as second-line
treatments, generally used in combination with metformin [6]. Sulfonylureas, the oldest oral anti-
diabetic agents, result in effective glucose-lowering but are associated with weight gain and an
increased risk of hypoglycemia [7]. Pioglitazone, a member of the thiazolidinedione (TZD) drug
class, may offer cardiovascular benefits [8, 9, 10, 11], although it is recommended that pioglitazone
should be avoided in patients with or at risk for heart failure because of its potential to cause
fluid retention [12]. For the more recently introduced dipeptidyl peptidase-4 inhibitors (DPP-
4i), prospective randomized trials have shown no association between DPP-4i and ischemic events
such as myocardial infarction or stroke, but their effects on the risk of heart failure is unclear
[13, 14, 15, 16].
A limited number of bimodal comparison studies have suggested either an increase in cardio-
vascular events with sulfonylureas or a decrease with metformin or pioglitazone [17, 18]. However,
the effects of each of these and other available non-insulin agents individually or with metformin on
cardiovascular events still remains uncertain, and future prospective, randomized trials to address
these questions are unlikely to be feasible.
The literature on causal inference with observational studies has generally been focused on
methodology for binary treatments [19, 20]. Yet, providers and patients frequently must choose
among several alternative treatments for type 2 diabetes. The propensity score, which is the prob-
ability of receiving treatment conditional on a set of observed covariates, is a common metric used
to adjust for observed differences in covariates between two treatment groups in non-randomized
observational studies [21]. For more than two treatment groups, the generalized propensity score
(GPS) vector represents the probability of receiving any one of the treatments, conditional on the
observed covariates [22, 23].
Inverse probability weighting and doubly robust estimators were proposed as possible solutions
to estimate causal effects in observational studies [24, 25, 26]. McCaffrey et al. [24] proposed a
method that combines a sandwich estimator with generalized boosted models to obtain point and
interval estimates for pairwise average treatment effects. Yoshida et al. [25] developed matching
weights to estimate pairwise average treatment effects across the entire population. Li and Li
[26] developed balancing weights to estimate pairwise differences in expectations among the sub-
population with the most overlap in covariates across all treatment groups. Possible limitations
of weighting methods are that they are limited to specific estimands (e.g., pairwise differences in
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expectations) and they may suffer from large biases and large standard errors in finite samples
because of extreme weights [27].
Matching algorithms have been proposed as a different approach to estimate causal effects of
multiple treatments [27, 28, 29, 30]. Scotina and Gutman [30] observed that matching on the GPS
performed well for five treatments or less, but as the number of interventions increases combining
matching with a clustering algorithm resulted in better reduction in initial bias. For multiple
treatments, statistically valid matching estimators were developed for continuous outcomes and
pairwise differences in expectations [29, 31]. Less attention has been given to other outcome types
(e.g., binary, time to event, etc.) and other estimands.
To overcome these limitations, we view causal effects as a missing data problem [32, 33] and
propose a combination of the Approximate Bayesian Bootstrap algorithm with k-means cluster-
ing on the GPS to estimate the causal effects of multiple treatments. The proposed procedure
provides statistically valid estimates for different types of outcomes and can be extended to pro-
vide interpretable sensitivity analyses. We implemented the proposed procedure to examine the
cardiovascular safety of three antihyperglycemic medications to metformin in patients with type 2
diabetes mellitus.
1.2 Framework
For units i = 1, . . . , n, let Y obsi , Xi, Wi, and Tiw be the observed outcome, set of P covariates,
treatment group identification such that Wi ∈ W = {1, . . . , Z}, and an indicator function that is
equal to 1 if unit i received treatment w and 0 otherwise. Define nw =
∑n
i=1 Tiw as the number of
units receiving treatment w, where
∑Z
w=1 nw = n.
A common assumption when estimating causal effects is the stable unit treatment value as-
sumption (SUTVA) [34], which requires that the potential outcomes for one unit are unaffected by
the treatment assignment of others, and that there are no multiple versions of treatment within
the same treatment group. Assuming SUTVA, the potential outcomes for unit i and treatment w
is Yi(Wi = w) = Yi(w) and Y
obs
i = Ti1Yi(1) + · · ·+ TiZYi(Z).
With nominal exposure, commonly used estimands of interest with continuous outcomes are the
population average treatment effects between treatment groups j and k for all pairs {j, k} ∈ W2,
over the group of units receiving reference treatment t [27],
τ tjk ≡ E [Y (j)− Y (k) |W = t] . (1)
This can be estimated by using the sample average treatment effect on the treated (ATT),
τˆ tjk ≡
1
nt
nt∑
i=1
Tit (Yi(j)− Yi(k)) . (2)
However, because only one of the potential outcomes is observed and realized for every unit,
an important piece of information needed to estimate τ tjk and is the assignment mechanism,
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P (W = t|X,Y (t)) [27, 32]. To estimate τ tjk, two restrictions are commonly made on the assignment
mechanism: (i) P (W = t | X, Y (t)) = P (W = t | X) ≡ r(t,X), and (ii) 0 < r(t,X) < 1 for all
t ∈ W [27]. These assumptions are also referred to as strong ignorability [22, 23].
With binary outcomes, τ tjk and measures the difference P (Yi(j) = 1 | Wi = t) − P (Yi(k) = 1 |
Wi = t) among units receiving treatment t. Other common estimands include the ratio of these
probabilities and their odds ratio [35].
The generalized propensity score (GPS) vector, R(X) = (r(1,X), . . . , r(Z,X)), is an extension of
the binary propensity score to multiple exposure levels. Under strong ignorability, comparing units
with similar R(X) results in well-defined causal effect estimates [23]. Generally, in observational
studies R(X) is unknown and only an estimate of it Rˆ(X) = {rˆ(1,X), . . . , rˆ(Z,X)} is available.
Estimating R(X) is part of the design phase, and several procedures have been described to estimate
it [27]. Here, we assume that the R(X) have been estimated to the satisfaction of the researcher
without observing any outcome data.
To obtain transitive causal effects estimates and to reduce extrapolation to units that have zero
probability of receiving one of the treatments, we restrict the analysis only to units “eligible” to
receive all treatments, also referred to as those within the range of common support [27, 36]. For
nominal exposure, Lopez and Gutman [27] proposed a rectangular common support region defined
by rˆ(w,X) ∈ (rˆmin(w,X), rˆmax(w,X)) for all w ∈ W, where
rˆmin(w,X) = max{min(rˆ(w,X |W = 1)), . . . ,min(rˆ(w,X |W = Z))}
rˆmax(w,X) = min{max(rˆ(w,X |W = 1)), . . . ,max(rˆ(w,X |W = Z))}.
The ATTs for units within this rectangular common support region are defined as
τ t,Ejk = E[Y (j)− Y (k) |W = t, Ei = 1],
where
Ei =
1, if rˆ(w,Xi) ∈ (rˆmin(w,Xi), rˆmax(w,Xi)) for all w ∈ W0, otherwise
2 Methodology
2.1 Matching estimators
Matching has been proposed as a method to estimate causal effects with multiple treatments. The
goal of matching is to balance the distribution of covariates across all treatment groups. Similarity
in covariates between units in different treatment groups is defined using a distance measure [30].
Examples of such distance measures include the linear GPS:
|logit(r(w,Xi))− logit(r(w,Xj))|, i 6= j ∈ {1, . . . , n}, w ∈ {1, . . . , Z},
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the Euclidean distance between R(Xi) and R(Xj),
{(R(Xi)−R(Xj))T(R(Xi)−R(Xj))}1/2 =
√√√√ Z∑
k=1
(r(k,Xi)− r(k,Xj))2,
and the Mahalanobis distance between two vectors Vi,Vj ∈ V,{
(Vi −Vj)TΣ−1(Vi −Vj)
}1/2
,
where Σ is the covariance matrix of Vi and Vj [27, 29, 30].
Using a selected distance measure, a common matching algorithm is 1:L nearest neighbor match-
ing, which selects for unit i in the reference treatment t the L individuals in each of the remaining
treatment groups with the smallest distance from unit i. When L = 1, each unit in the reference
treatment t is paired with its best match from each of the other treatment groups. Increasing
L improves precision by reducing the sampling errors, but this improvement may be hindered by
increasing bias that arises from the introduction of poorer matches [30, 37].
A different characteristic of matching algorithms is whether units can be used as matches
more than once. Matching “with replacement” can often decrease covariates’ bias because non-
reference group units that are similar to multiple reference group units can be matched multiple
times. However, in some cases matching with replacement may result in only a small number of
non-reference units being matched [19].
Scotina and Gutman [30] found that for five or fewer treatments, matching with replacement on
the Mahalanobis distance of the logit GPS vector provided the largest reduction in initial covariate
bias between treatment groups. This algorithm was defined as LGPSMnc by [30]. As the number
of treatments increases, matching on this distance measure performs worse in terms of reducing
initial covariates’ bias, because the dimension of the GPS vector increases. With more than five
treatments, combining a clustering step with matching on the Mahalanobis distance of the logit
GPS resulted in larger reduction in covariates’ bias, compared to only matching on the Mahalanobis
distance of the logit GPS vector.
Development of inference procedures for causal effect estimation with multiple treatments in
matched cohorts has been limited. For matching with replacement, asymptotic point and inter-
val estimators were derived for continuous outcomes and differences in means [29, 31]. However,
the performance of these estimators has not been examined for other types of outcomes and esti-
mands. With binary treatment, the bootstrap estimator was found to provide valid inferences when
matching without replacement [38]. On the other hand, Abadie and Imbens [39] showed that for
matching with replacement the bootstrap method may be statistically invalid in certain situations.
The bootstrap estimator was not examined for multiple treatments.
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2.2 Weighting estimators
Inverse probability weighting (IPW) is a common approach for estimating causal effects with mul-
tiple treatments [24, 25, 26, 40]. Li and Li [26] proposed a general framework for estimating causal
effects using generalized propensity score weighting with multiple treatments. Assuming weak
unconfoundedness [22], τ tjk can be estimated as
τˆ t,IPWjk = E[Yˆi(j))− E(Yˆi(k)]
=
( n∑
i=1
I(Wi = j)Y obsi r(t,Xi)
r(j,Xi)
)
×
(
n∑
i=1
I(Wi = j)r(t,Xi)
r(j,Xi)
)−1
−
( n∑
i=1
I(Wi = k)Y obsi r(t,Xi)
r(k,Xi)
)
×
(
n∑
i=1
I(Wi = k)r(t,Xi)
r(k,Xi)
)−1 ,
where r(j,Xi), r(k,Xi), and r(t,Xi) are commonly unknown, and replaced with their corresponding
estimates rˆ(j,Xi), rˆ(k,Xi), and rˆ(t,Xi). To calculate the sampling variance of this estimate, the
sandwich estimator, which takes into account the uncertainty in the estimated propensity score, is
commonly implemented [24, 26].
For binary treatment, Gutman and Rubin [33, 41] found that IPW is generally statistically
valid, but it is susceptible to extreme weights, which could yield erratic causal estimates. This is
exacerbated with a large number of treatments and non-normally distributed covariates [27, 31].
2.3 Imputation procedures
Weighting and matching methods implicitly impute the unobserved potential outcomes. A different
approach is to explicitly impute the missing potential outcomes [32, 33, 42]. The imputation
procedures proposed in this paper aim to impute the values of missing potential outcomes in each
treatment group. Let Yobst = {Y obsi : Wi = t} be the set of observed potential outcomes for
treatment t, let Ymist,t′ = {Yi(t′) : Wi = t, t′ 6= t ∈ W} be the missing potential outcomes for
treatment t′, for the set of units which received treatment t. A Bayesian approach to missing data
imputation samples from the posterior predictive distribution, P (Y mist,t′ | Y obs). Let P (Y obst | θ) be
the sampling distribution, where θ are the parameters governing distribution with prior distribution
P (θ). Assuming that Y mist,t′ is independent from Y
obs given θ, then samples for P (Y mist,t′ | Y obs) can
be obtained by first drawing θ∗ from its posterior distribution, P (θ|Y obs) ∝ P (θ)P (Y obs|θ), and
then drawing Ymist,t′ , conditional on θ
∗ [43, 44].
2.3.1 Hot deck imputation
Hot deck methods were proposed as possible techniques to impute missing data [45]. These methods
replace missing values of one unit (the “recipient”) with observed values from another unit (the
“donor”). Two common implementations of hot deck imputation methods are the random hot
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deck and the deterministic hot deck imputation. In the random hot deck imputation, the donor
is randomly selected from a set of potential donors, where “potential” is defined according to a
distance metric. In the deterministic hot deck imputation, a single donor is identified using a
nearest neighbor approach based on a distance metric [45, 46].
The distance measures that were described in Section 2.1 can be used to create donor pools
for hot deck methods. For imputing missing potential outcomes when comparing multiple treat-
ments, one possible procedure to create donor pools is based on k-means clustering [46]. This
procedures creates donor pools using k-means clustering on the logit transformation of Rˆ(X),
such that patients within each cluster are roughly similar on each component of logit(Rˆ(X)) =
(logit(rˆ(1,X)), . . . , logit(rˆ(Z,X))), and there is at least one patient from each treatment group in
each cluster. Imputation is then performed within each cluster separately. A limitation of this clus-
tering approach is that with a large number of clusters, one or more treatment groups may have a
small number or no individuals within a cluster, which would require extrapolation to that cluster
[27]. Another limitation of hot deck imputation is that it is not a proper Bayesian imputation
method, which results in an underestimation of the sampling variance [45, 47].
2.3.2 Approximate Bayesian Bootstrap multiple imputation
The Bayesian Bootstrap was proposed as an imputation method, which is based on observed values
and reflects the uncertainty in the estimation of population parameters [47]. For a categorical
outcome variable, let θ = (θ1, . . . , θL) represent the probabilities of the outcome taking values
d1, . . . , dL. Assuming the prior distribution P (θ) ∝
∏L
l=1 θ
−1
l , then the posterior distribution
is P (θ|Y obst ) ∝
∏L
l=1 θ
ql−1, where ql is the number of times that the value dl appears in Y obst .
The Bayesian Bootstrap algorithm draws θ∗ from P (θ|Y obst ), then Y mist,t′ are drawn independently
from d1, . . . , dl with probability θ
∗
1, . . . , θ
∗
l [47]. The Approximate Bayesian Bootstrap (ABB) was
proposed as computationally simpler approximation of the Bayesian Bootstrap [47]. For treatments
t and t′ 6= t, ABB imputes the missing potential outcomes Ymist,t′ for treatment group t by: (i)
drawing nt′ components with replacement from Y
obs
t′ ; (ii) drawing nt components with replacement
from the nt′ deaws in (i). This double resampling procedure approximates the Bayesian Bootstrap
and results in valid statistical inference [48]. Both the Bayesian Bootstrap and the ABB do not
adjust for potential covariates. Lavori [49] proposed a procedure that performs the ABB within
propensity score subclasses.
We propose a procedure that combines k-means clustering with multiple imputation using ABB
to estimate causal effects of multiple treatments. Formally, to estimate τ tjk:
1. Partition patients into Q subclasses based on logit(Rˆ(X)) using k-means clustering, and
ensure that there is at least one treated unit from each treatment group in each cluster.
2. Within each cluster q ∈ {1, . . . , Q}:
(a) Let Oqw be the set of units in subclass q which received treatment w, and let n
q
w = |Oqw|
be the cardinality of Oqw. For each treatment w 6= t ∈ W, draw nqw values from Oqw with
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replacement, where each element has 1/nqw probability of being selected. This forms the
donor pool, O˜qw, for each treatment w.
(b) For each w, draw nqt values from O˜
q
w with replacement. Each of the elements in O˜
q
w has
equal probability of being selected.
3. Repeat steps 2(a) and 2(b) M = 25 times.
This creates M imputed datasets, each containing imputed missing potential outcomes for patients
in treatment group t.
Let τˆ
t(m)
jk denote the estimated ATT between treatments j and k from imputed dataset m =
1, . . . ,M , and let Vˆ
(m)
jk be its estimated sampling variance. The point estimate for τ
t
jk is
τˆ tjk =
1
M
M∑
m=1
τˆ
t(m)
jk ,
and the standard error is estimated by√√√√ 1
M − 1
M∑
m=1
(
τˆ
t(m)
jk − τˆjk
)2
+
1
M
M∑
m=1
Vˆ
(m)
jk .
While we use M = 25 imputations, the standard error can be estimated using percentiles of τˆ
t(m)
jk
when M > 100 [33].
One limitation of implicit imputation methods such as weighting and matching is that inference
is generally limited to specific estimands. Obtaining interval estimates for other estimands is
generally complex and relies on asymptotic approximations. An advantage of the proposed ABB
procedure is that it can provide valid inference for any estimand, because it explicitly imputes the
missing potential outcomes.
3 Simulation Study
3.1 Design
To examine the operating characteristics of the different procedures, we constructed simulation
analyses. The first set of factors describes the covariate distributions of Z = 3 treatment groups,
which are either known to the investigator, or can be estimated without outcome data. The second
set of factors describes the response surfaces, which are unknown to the investigator.
We generated the P = 18 covariates’ values for n1 = 1200, n2 = 2400, and n3 = 4800 units
receiving treatments 1, 2, and 3, respectively, from multivariate skew-t distributions with 7 degrees
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of freedom [50]:
Xi | {Wi = 1} ∼ Skew-t7,18(µ1, I18,η), i = 1, . . . , n1,
Xi | {Wi = 2} ∼ Skew-t7,18(µ2, I18,η), i = n1 + 1, . . . , n1 + n2,
Xi | {Wi = 3} ∼ Skew-t7,18(µ3, I18,η), i = n1 + n2 + 1, . . . , n1 + n2 + n3,
where µw = vec(1P ⊗ bw), where 1P is a P × 1 vector of 1s, and bw is a 3× 1 vector such that the
w value is equal to b and the rest are zeros, b ∈ {0, 0.25, 0.50, 0.75, 1}. As the value of b increases
there is larger initial bias across the different treatment groups.
We assumed that Yi(w) ∈ {d1, . . . , dL}, and we only examined monotone response surfaces.
Binary potential outcomes, Yi(w) ∈ {0, 1}, were simulated from Bernoulli distributions with success
probability G−11 (Xiβ
′
X) in reference treatment group 1, G
−1
2 (γXiβ
′
X) in treatment group 2, and
G−13 (γXiβ
′
X) in treatment group 3, where βX = (2, 4, 6, 1, . . . , 1) is a P × 1 vector that governs
the association between Xi and Yi(w). When γ = −1 the response surfaces for treatment groups
2 and 3 are mirror images of the response surface in treatment group 1 multiplied by a constant.
We used two link functions for monotone response surfaces: the logistic, and the normal (probit),
both of which are symmetric.
For ordinal Yi(w) ∈ {1, 2, 3, 4, 5}, the values were simulated using the proportional odds model,
logit[P (Yi(w) ≤ j | Xi)] = αj + Xiβ′X j = 1, . . . , 4,
where α1 = 1, α2 = 0.05, α3 = −0.05, and α4 = −1.
The simulations were performed as a full factorial design of the factors described in Table 1.
Each simulation configuration was replicated 200 times. At each replication `, ` = 1, . . . , 200, we
estimated each pairwise ATT and the standard error, for each of the procedures. Using these values
we recorded at each replication the following measures:
bias`(j,k) = τˆ
t
`(j,k) − τ t`(j,k)
coverage`(j,k) =
{
1 if τ t`(j,k) ∈ τˆ t`(j,k) ± 1.96× SE(τˆ t`(j,k)), 0 otherwise
}
Table 1: Simulation factors
Factor Levels of factor
b {0, 0.25, 0.50, 0.75, 1.00}
η {−3.5, 0, 3.5}
γ {−1, 1}
Gw {logistic,probit}
To summarize the bias, we calculated the mean and standard deviation of |bias`(j,k)| across the
200 replications. The median SE(τˆ t`(j,k)) across the 200 replications was used to summarize the
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standard errors of each pairwise comparison.
We summarized matching performance using maximum absolute standardized pairwise bias,
Max2SBp, for each pair of treatments and each covariate p,
Max2SBp = max (|SBp12|, |SBp13|, |SBp23|, . . . ) ,
This metric reflects the largest discrepancy in estimated means between any two treatment groups
for covariate p [24, 27, 30]. McCaffrey et al. [24] advocated a cutoff of 0.20 but maintained that
larger cutoffs may be appropriate for different applications. We summarized this metric over all co-
variates for each replication by calculating the maximum bias, MaxMax2SB = maxp=1,...,P (Max2SBp).
To summarize clustering performance, the SBpjk were calculated within each cluster and weighted
across clusters, with weights proportional to the number of units within each cluster.
The following methods were compared: nearest neighbor matching for multiple treatments using
the LGPSMnc algorithm from Scotina and Gutman [30], IPW [24], and ABB multiple imputation
with k-means clustering using Q ∈ {1, 3, 5, 7} clusters.
3.2 Results for clustering and matching performance
Covariates’ balance across treatment groups for k-means clustering and matching is depicted in
Figure 1. For each level of Q and matching, MaxMax2SB increases with b and it is largest for
b = 1.00. This trend is the strongest for matching, where its largest MaxMax2SB is 1.06 for
b = 1.00. ABB with k-means clustering with Q = 3 was most resistant to an increase in b, where
its MaxMax2SB of 0.55 for b = 1 was the smallest of the examined procedures. For small values
of b matching had the smallest MaxMax2SB.
3.3 Results for 95% interval coverage, bias, and standard error
To identify the simulations’ factor with the largest influence on the performance of the different
estimation methods, we examined the factors’ MSE for interval coverage between treatments 1 and
2 and treatments 1 and 3 (as in the works of Lopez and Gutman, Scotina and Gutman, and Cangul
et al. [27, 30, 51]). Across all of the methods that were examined, initial covariates’ bias, b, was
found to be the most influential factor on coverage rates.
We will begin by describing the simulation results for Yi(w) ∈ {0, 1}. Tables 2 and 3 show the
95% coverage rates, mean absolute bias, and standard errors for the ATT measured as pairwise
risk differences with treatment group 1 as the reference across levels of b when the treatment effect
is null or non-null, respectively. When there is small initial bias, all of the methods perform well
with IPW having the smallest standard errors. However, as the initial bias increases, ABB with
either 5 or 7 clusters generally has the smallest absolute bias and standard errors. ABB with Q = 7
clusters generally results smaller average absolute bias for b ≤ 0.5 compared to Q = 5, while ABB
with Q = 5 results in smaller average absolute biases for b > 0.5. In addition, ABB with Q = 5
yields coverages that are at or above nominal for both null and non-null treatment effects for each
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Figure 1: MaxMax2SB across different levels of b for ABB and matching
level of b. ABB with Q = 1 cluster is only valid when b < 0.25. For b ≥ 0.50, IPW yielded the
largest mean absolute bias and standard error, which results in coverage rates that are lower than
nominal. For b ≤ 0.50, matching estimators yield nominal coverage rates, with mean absolute
biases and standard errors that are similar to those obtained using ABB with Q ∈ {3, 5, 7}. For
b ≥ 0.75, matching estimator coverage rates are below nominal, and the mean absolute biases and
standard errors are larger than the ones observed for ABB with Q ∈ {5, 7} clusters.
Because ABB with k-means clustering is not restricted to a specific estimand, we examined its
performance for estimating the log odds ratio and the log risk ratios. Tables 6–9 display the 95%
coverage, mean absolute bias and standard errors across the different levels of b. The results are
generally similar to the ones observed for risk differences. Specifically, ABB with Q ∈ {5, 7} clusters
generally has coverages that are close to nominal. Both methods may result in undercoverage when
the initial bias is large.
The results for ordinal outcomes are similar to the ones observed for binary outcomes. Table 10
shows the 95% coverage rates, mean absolute bias, and standard errors for the ATT measured as
pairwise risk differences with treatment group 1 as the reference across levels of b when the outcome
is ordinal. Each of the examined methods perform well with small initial bias. ABB with either
5 or 7 clusters generally yield the smallest absolute bias and standard errors as the initial bias
increases.
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4 Cardiovascular safety of second-line non-insulin antihyperglycemic
therapy
4.1 Data description
The Clinical Practice Research Datalink (CPRD), established in 1987, is a longitudinal, anonymized
database which includes more than 13 million people enrolled from over 600 general practitioners
in the United Kingdom (U.K.). Available data include basic patient demographics and registration
details, medical history events including symptoms, signs and diagnoses, clinical test data, and
details of all issued prescriptions. In addition, the general practitioners’ practice postcodes and
eligible patient residence postcodes are linked to neighborhood characteristics to obtain measures
of area level deprivation and a rural-urban classification.
The CPRD represents complete data from the U.K. National Healthcare System, and previous
validation studies have reported on the accuracy of its diagnostic data [52]. Diagnostic information
in the CPRD is coded using Read codes, the standard clinical terminology system used in the U.K.
A subset of patients is linked to additional datasets from the Hospital Episode Statistics inpatient
data, which include information about National Health Service inpatient visits. To ensure that we
have complete hospitalizations records we restricted the analysis only to the subset of patients that
can be linked. Primary and additional causes of hospital admissions are coded using ICD-10 codes.
We restrict our analysis to CPRD patients who were new users of antihyperglycemic treatments.
Specifically, to be included in the study patients had (i) received their first ever prescription for
a second-line therapy for type 2 diabetes mellitus between January 2007 and December 2013, and
used it for 60 days; (ii) had at least six months of continuous follow-up prior to the cohort entry
date; (iii) had a diagnosis of type 2 diabetes mellitus at anytime prior to the date of initiation of the
second-line therapy. The index date was defined as 60 days after the first filled prescription for the
second-line agent, and patients were grouped based on their second-line antihyperglycemic regimen:
sulfonylurea (SU), dipeptidyl peptidase-4 (DPP-4) inhibitor, or thiazolidinedione (TZD). Because
the majority of patients initiated dual-therapy with gliclazide (G) (90% of SU users), sitagliptin
(S) (72% of DPP-4i users), or pioglitazone (P) (83% of TZD users), we further restricted the study
population to patients who initiated dual-therapy with one of these three agents. The analyses were
performed using an intention-to-treat approach, such that patients were assigned to a cohort once
they met the criteria, regardless of future changes in treatment regimen not otherwise specified,
such as adding a third agent (see Appendix for a summary of cohort selection).
Covariates included demographics (e.g., age, sex, race, etc.), clinical measurements (e.g., HbA1c,
BMI, LDL cholesterol, etc.), comorbidities, concurrent medication use, year of the index date,
diabetes duration until the index date, and time on metformin before add-on initiation. Duration
of diabetes was calculated from the date of first observed diabetes claim to the index date, and time
on metformin was calculated from the date of first metformin use to the index date. Comorbidities
were defined if they were diagnosed within two years prior to the index date, and concurrent
medication use was defined as at least one filled prescription in the year prior to the index date.
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The primary analysis was the average treatment effect among gliclazide add-on users, estimated
using three-year pairwise risk differences of major adverse cardiovascular events (MACE) and all-
cause mortality (ACM). MACE included fatal/non-fatal CVD including myocardial infarction,
fatal/non-fatal CHF, and stroke. These outcome events were ascertained using ICD-10 codes for
patients linked with Hospital Episode Statistics (see Appendix for ICD-10 codes) and Read codes
for the rest [53].
Table 4 lists the covariates, along with a p-value testing the null hypothesis of no dependency
between second-line treatment initiation and each covariate. To estimate the GPS model, we
used a multinomial logistic regression model that included all of the baseline covariates in Table 4
as explanatory variables. Causal effects were estimated using ABB with k-means clustering on
logit(Rˆ(X)) with Q ∈ {1, 3, 5, 7} clusters, 1:1:1 nearest neighbor matching on the Mahalanobis
distance of the logit GPS vector with replacement [30], and IPW [24]. Because some of the baseline
covariates had missing values, we created 20 multiple complete datasets by applying the fully
conditional specification approach in each arm separately using the mice package [54]. We restricted
the analysis only to units within the range of common support, Ei. IPW and matching were
implemented in each imputed dataset and the results were combined using the common multiple
imputation rules [55]. When using ABB, imputation was performed in each of the complete datasets
and final point and interval estimates were obtained using the common combination rules for two-
stage imputation [56].
Of the 15,484 metformin users included in the analysis, 10,487 (68%) had initiated dual-therapy
with gliclazide, 3,180 (21%) with sitagliptin and 1,817 (12%) with pioglitazone. The median patient
age was between 60 and 61 years for each group. Diabetes duration was less than five years for 82%
of the patients and between five and ten years for 18% of the patients. Median time on metformin
monotherapy was approximately 2.5-2.6 years for all groups. HbA1c levels were between 8.4-8.7 for
each group, reflecting similar blood glucose control. Pioglitazone users had the highest prevalence
of hypertension, neuropathy, and retinopathy at initiation.
4.2 Results
Covariate balance diagnostics in the form of Max2SBp in the initial cohort and the cohort after
matching or clustering are given in Figures 2 and 3. Reduction in initial bias was observed for
most of the covariates using either clustering or matching. Except for diabetes duration with the
matching algorithm, all of the Max2SBp were smaller than 0.2 for both clustering and matching
algorithms. Compared to matching, ABB with k-means clustering with Q = 5 yielded a larger
reduction overall in covariate bias between treatment groups (MaxMax2SB = 0.1727 for ABB
with Q = 5, MaxMax2SB = 0.2631 for LGPSMnc).
We set metformin plus gliclazide as the reference level. The estimated causal effects in the three-
year risk of MACE or ACM using ABB with k-means clustering, matching, and IPW are depicted
in Table 5. The baseline rates of MACE and ACM when using ABB for each of the three second-line
treatment groups is given in Table 11 in the Appendix. Pairwise comparisons between gliclazide and
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Figure 2: Max2SBp before and after ABB with k-means clustering (Q = 5)
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
lNitrates
Loop Diuretics
Lipid−Lowering
CCBs
Beta Blockers
Aspirin
Anti−psychotics
Anti−arrhythmics
Ace Inhibitors
Stroke
Renal Disease
Retinopathy
Neuropathy
Hypertension
Heart Failure
Falls
COPD
CHD
Cancer
Atrial Fibrilation
Arrhythmia
Smoking
Triglycerides
BMI
DBP
SBP
Creatinine
LDL
HbA1c
Time on Metformin
Diabetes Duration
Deprivation (5)Deprivation (4)
Deprivation (3)Deprivation (2)
Deprivation (1)Hispanic/Other
Black
White
Sex
Age
0.0 0.1 0.2 0.3
Max2SB (before and after matching)
l
l
Max2SB (pre−matched)
Max2SB (matched)
Matching on the GPS vector
Figure 3: Max2SBp before and after LGPSMnc matching
14
pioglitazone yielded uniformly positive and statistically significant differences in three-year risk of
MACE, with the effect size ranging from a 3.2% (IPW) to a 4.6% (ABB with Q = 1) higher risk of
MACE for gliclazide second-line users. Pairwise comparisons between sitagliptin and pioglitazone
users also yielded uniformly positive and statistically significant differences in three-year risk of
MACE. Pairwise comparisons between gliclazide and sitagliptin yielded uniformly positive and
statistically significant differences in three-year risk of ACM, with the effect size ranging from 0.9%
(matching and IPW) to 1.6% (ABB with Q = 1) higher risk of ACM for gliclazide second-line users.
Pairwise comparisons between gliclazide and pioglitazone and sitagliptin and pioglitazone yielded
uniformly small and non-statistically significant differences in three-year risk of ACM. Similar trends
occur when using the three-year risk ratio with ABB, shown in Table 12 in the Appendix.
Generally, ABB with Q = 1 reports larger differences than the other methods. The most
notable difference in estimated three-year risk differences is observed when comparing gliclazide and
sitagliptin risk of MACE. ABB with Q = 1 yielded a positive, statistically significant difference in
three-year risk of MACE, with an effect size of 1.6%. However, when using ABB with Q ∈ {3, 5, 7},
matching or IPW, the effect sizes are not statistically significant. These results are similar to those
found in the simulations, where ABB with Q = 1 results in be biased estimates and coverage
rates that are below nominal when estimating a null ATT. When comparing ABB with Q ∈ {5, 7}
to matching and IPW, only minor differences are observed for the point and interval estimates
of ACM. However, larger differences in point estimates are observed when comparing MACE for
gliclazie and sitagliptin. Matching and IPW point estimates indicate that gliclazide has a lower
probability of MACE compared sitagliptin and ABB with Q ∈ {5, 7} indicate a higher probability.
The interval estimates of all these methods overlapped and included 0.
4.3 Sensitivity analysis
All of the proposed methods rely on the strong ignorability assumption which is untestable with
observed data. To examine the validity of this assumption with ABB, we propose an interpretable
sensitivity analysis.
We examine the sensitivity of the τGG,S and τ
G
G,P to an unmeasured covariate by introducing
a continuous variable ξ that is independent from the observed covariates. We assume that ξi is
Normally distributed with mean δY obsi +φTi,S+φTi,P and a variance of 1. In this model, φ represents
the initial bias in ξi when comparing gliclazide to sitagliptin or gliclazide to pioglitazone, and exp(δ)
represents the odds ratio of Y obsi ∈ {0, 1} given an increase of one unit in ξi.
To provide intuition to this sensitivity analysis, it is useful to consider two possible scenarios.
The first scenario is when the signs of δ and φ are the same. Under this scenario, the distribution of
ξ with Y obsi = 1 among gliclazide users is more similar to the distribution of ξ with Y
obs
i = 0 among
pioglitazone or sitagliptin users. Thus, these units would be more similar when ξ is included in
the generalized propensity score estimation, which will yield a larger estimated ATT. In the second
scenario, the signs of δ and φ are opposite. As a consequence, the distribution of ξ with Y obsi = 0
among gliclazide users is more similar to the distribution of ξ with Y obsi = 1 among pioglitazone
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or sitagliptin users. This scenario will yield a smaller estimated ATT when ξ is included in the
generalized propensity score estimation.
We estimated τˆGG,S and τˆ
G
G,P for MACE using the observed data and ξ. The GPS estimation
included ξ as another covariate in the multinomial logistic regression model, and used ABB with
k-means clustering that assumed Q = 5. Figure 4 displays the standardized effects, τˆGG,S/SE(τˆ
G
G,S)
and τˆGG,P /SE(τˆ
G
G,P ) for MACE, for φ ∈ (−1, 1) and for δ ∈ (−1, 1).
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Figure 4: Standardized effect for varying δ and φ, 3-year MACE risk
Based on Table 5, the standardized difference in MACE risks between gliclazide and sitagliptin
16
is close to zero before introducing ξ (e.g. φ = 0 and δ = 0). When incorporating ξ into the
estimation procedure, the standardized effects are most sensitive to configurations with |δ| ≥ 0.5 and
|φ| ≥ 0.5. The absolute value of the standardized effect was greater than 2 for these configurations.
This implies that in order to find a statistically significant effect, the unobserved covariate should
have a standardized initial bias greater than 0.5 or an odds ratio that is greater than exp(0.5).
The standardized difference in MACE risks between gliclazide and pioglitazone is equal to 3.99
before introducing ξ. When incorporating ξ in these comparisons, the standardized effects are
most sensitive to {0.5 ≤ δ < 1} ∩ {−1 < φ ≤ −0.5} and {−1 < δ ≤ −0.5} ∩ {0.5 ≤ φ < 1}, where
the standardized effect approached 0 for these configurations. None of the observed covariates had
initial bias that is greater than 0.3. In addition, an odds ratio of 1.6 is similar to a moderate Cohen’s
d [57]. Thus, we can conclude that the estimates are relatively robust to the strong ignorability
assumption.
5 Discussion
Many problems in public health involve comparing three or more interventions. This paper pro-
poses an approximate Bayesian bootstrap (ABB) procedure that uses k-means clustering on the
generalized propensity score (GPS) to estimate causal effects of multiple nominal treatments. The
k-means clustering component ensures that donors have relatively similar covariate values, and the
ABB component imputes the unobserved potential outcomes. This procedure can be used with
binary or categorical outcomes, and it provides a statistically valid inference procedure for any
estimand. We also describe a sensitivity analysis to the strong ignorability assumption. The sen-
sitivity analysis can be implemented within the proposed ABB procedure and it is interpretable
using graphical visualization.
Using simulations, we compared the performance of the newly proposed procedures to matching
and IPW estimators. For these simulation configurations we observed that ABB with k-means
clustering is generally accurate and precise when using 5 or 7 clusters compared to weighting and
matching methods.
The simulation study used Z = 3 treatment groups and the logit GPS vector as a distance
measure for k-means clustering and matching. Scotina and Gutman [30] found that this distance
measure can perform poorly in terms of reducing covariate bias between treatment groups, when
used in matching algorithms with Z > 5. An area for future work would be to identify the operating
characteristics for ABB multiple imputation with k-means clustering when there is a large number
of treatments. ABB with k-means clustering only imputes the missing potential outcomes based on
the GPS. A potential extension would be to impute missing potential outcomes based on a model
that includes the generalized propensity score and covariates that predict the outcome. This type
of modeling was shown to yield more precise and accurate estimates with two treatments [33, 58].
For the nearly 20 million people affected with type 2 diabetes in the United States, acute
myocardial infarction is a very serious and potentially fatal complication of the disease, the choices
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of treatments are highly complex [59], and the effects of various antihyperglycemic treatments
on macrovascular events is uncertain [60, 61]. The analysis presented here is a novel approach
to comparing the risks of major adverse cardiovascular events (MACE) and all-cause mortality
(ACM) of multiple second-line antidiabetic medications using observational data [9, 53, 62]. We
show that, among patients who initiate second-line treatment after metformin monotherapy, there
is a significantly higher three-year risk of MACE for users of gliclazide and sitagliptin compared to
users of pioglitazone. Further, there is a significantly higher three-year risk of ACM for gliclazide
second-line users compared to sitagliptin second-line users. It will be of interest to explore the use
of this methodology to investigate the effects of these antihyperglycemic agents and other members
of the sulfonylurea and DPP-4i drug classes in other large clinical databases. As more real-world
clinical data with new antihyperglycemic agents that have shown evidence for cardiovascular benefit,
such as members of the sodium glucose co-transporter 2 inhibitor class [63, 64], become available,
it will be of interest to determine whether the observations from prospective, randomized clinical
trials with these agents are confirmed.
In conclusion, we provide a general method for estimating causal effects using the generalized
propensity score that can be applied to binary or categorical outcomes and any estimand of interest.
Based on our simulations, ABB with k-means clustering using K ∈ {5, 7} clusters generally yields
valid, accurate, and precise estimates of average treatment effects.
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6 Appendix
6.1 Cohort information
Patients treated with metformin
between January 2004 and De-
cember 2015 (n = 103690)
Excluded (n = 44215):
Patients on metformin
monotherapy only
Patients treated with metformin monother-
apy for at least 60 days (n = 34959)
Excluded (n = 4274):
Patients who changed
from metformin mono-
therapy to monotherapy
of a different agent
Patients who started continuous treat-
ment of a second non-insulin antihyper-
glycemic agent and who maintain continuous
treatment of metformin (n = 25924)
Excluded (n = 981):
Patients who used SGLT-
2i or GLP-1RA as second-
line agent
Patients age 18-85, BMI 18.5-50
kg/m2, serum creatinine 20-250
µmol/l, and second-line treatment ini-
tiation 2007 or later (n = 21976)
Patients who used gliclazide, sitagliptin, or
pioglitazone as second-line agent (n = 18543)
Excluded (n = 3059):
Patients outside the
region of
common support
Treatment regimens:
1) Metformin + SU (n = 10487)
2) Metformin + DPP-4 (n = 3180)
3) Metformin + TZD (n = 1817)
Figure 5: Description of cohort selection
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6.2 ICD-10 Codes for Outcome Events
• I20-I25: Ischemic heart diseases
• I70.2: Atherosclerosis of native arteries of the extremities
• I73.1: Thromboangiitis obliterans
• I73.9: Peripheral vascular disease (unspecified)
• E10.5: Type 1 diabetes mellitus with circulatory complications
• E11.5: Type 2 diabetes mellitus with circulatory complications
• I50: Heart failure
• I61-64: Nontraumatic intracerebral hemorrhage, other and unspecified nontraumatic intracra-
nial hemorrhage, cerebral infarction, stroke (unspecified)
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Table 4: Baseline characteristics for patients within the region of common support, cohorts defined
by second-line treatment allocation
Variable Gliclazide Sitagliptin Pioglitazone p-value
No. of patients 10487 3180 1817
Age, years 61 (11) 60 (11) 60 (12) < 0.001
Women, n (%) 3990 (38.0) 1202 (37.8) 620 (34.1) 0.006
Race, n (%) 0.266
White 9522 (90.8) 2891 (90.9) 1669 (91.9)
Black 181 (1.7) 44 (1.4) 21 (1.2)
Hispanic/other 784 (7.5) 245 (7.7) 127 (7.0)
Deprivation index 3 (2) 3 (2) 3 (2) 0.007
Smoking, n (%)
Smoker 2335 (18.2) 717 (16.7) 353 (18.3) 0.144
Year, index date, n (%)
2007 979 (9.3) 28 (0.9) 276 (15.2)
2008 1441 (13.7) 141(4.4) 403 (22.2)
2009 1933 (18.4) 380 (11.9) 407 (22.4)
2010 1840 (17.5) 738 (23.2) 360 (19.8)
2011 1642 (15.7) 717 (22.5) 244 (13.4)
2012 1504 (14.3) 691 (21.7) 75 (4.1)
2013 1148 (10.9) 485 (15.3) 52 (2.9)
Diabetes duration, years 3.3 (1.8) 3.7 (1.9) 3.2 (1.5) < 0.001
Time on metformin, years 2.5 (1.9) 2.6 (2.0) 2.6 (2.0) 0.027
HbA1c, % 8.7 (1.6) 8.4 (1.5) 8.5 (1.5) < 0.001
BMI, kg/m2 32.1 (5.4) 32.7 (5.6) 31.8 (5.8) < 0.001
LDL cholesterol, mmol/L 2.3 (0.8) 2.3 (0.8) 2.3 (0.8) < 0.001
Serum creatinine, mmol/L 81 (19) 79 (18) 82 (19) < 0.001
Systolic BP 138 (10) 137 (10) 137 (10) < 0.001
Diastolic BP 81 (6) 81 (6) 80 (6) < 0.001
Triglycerides, mmol/L 2.3 (1.3) 2.2 (1.2) 2.2 (1.2) 0.001
Comorbidity, n (%)
CVD 837 (8.0) 202 (6.4) 113 (6.2) 0.002
CHF 342 (3.3) 90 (2.8) 44 (2.4) 0.107
Stroke 436 (4.2) 100 (3.1) 64 (3.5) 0.025
AF 563 (5.4) 147 (4.6) 92 (5.1) 0.244
Cancer 712 (6.8) 173 (5.4) 111 (6.1) 0.021
Arrhythmia 626 (6.0) 170 (5.3) 97 (5.3) 0.295
COPD 622 (5.9) 133 (4.2) 93 (5.1) 0.001
Hypertension 1535 (14.6) 349 (11.0) 270 (14.9) < 0.001
Neuropathy 573 (5.5) 162 (5.1) 118 (6.5) 0.106
Retinopathy 2671 (25.5) 712 (22.4) 518 (28.5) < 0.001
Renal disease 86 (0.8) 18 (0.6) 9 (0.5) 0.154
Falls 799 (7.6) 199 (6.3) 170 (9.4) < 0.001
Concurrent medication, n (%)
ACE/ARB 6466 (61.7) 1977 (62.2) 1124 (61.9) 0.871
β-blockers 214 (2.0) 67 (2.1) 27 (1.5) 0.256
CCBs 2028 (19.3) 637 (19.7) 325 (17.9) 0.263
Statins 8674 (82.7) 2681 (84.3) 1544 (85.0) 0.014
Antiarrhythmics 135 (1.3) 28 (0.9) 17 (0.9) 0.109
Antipsychotics 40 (0.4) 9 (0.3) 3 (0.2) 0.287
Loop diuretics 935 (8.9) 269 (8.5) 100 (5.5) < 0.001
Nitrates 389 (3.7) 120 (3.8) 53 (2.9) 0.221
Aspirin 4347 (31.5) 1211 (38.1) 806 (44.4) < 0.001
∗Descriptive statistics are presented as the median (IQR) for continuous variables, unless otherwise indicated.
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Table 5: Estimated 3-year risk difference (expressed as %) for MACE and ACM (standard errors
in parentheses) among gliclazide second-line users
Outcome Method Gliclazide vs. Sitagliptin Gliclazide vs. Pioglitazone
MACE ABB
Q = 1 1.6 (0.8)∗ 4.6 (0.8)∗
Q = 3 0.1 (0.8) 4.4 (0.9)∗
Q = 5 0.1 (0.9) 3.7 (0.9)∗
Q = 7 0.1 (0.9) 3.5 (0.9)∗
Matching -0.1 (0.8) 3.6 (1.0)∗
IPW -0.4 (0.8) 3.2 (0.9)∗
ACM ABB
Q = 1 1.6 (0.4)∗ 0.7 (0.5)
Q = 3 1.2 (0.4)∗ 0.4 (0.6)
Q = 5 1.2 (0.5)∗ 0.3 (0.6)
Q = 7 1.1 (0.4)∗ 0.5 (0.5)
Matching 0.9 (0.4)∗ 0.5 (0.6)
IPW 0.9 (0.4)∗ 0.3 (0.5)
∗Significant at the 0.05 level
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Table 11: Estimated 3-year rates (expressed as %) for MACE and ACM (with 95% confidence
interval) among gliclazide second-line users
Outcome Method Gliclazide Sitagliptin Pioglitazone
MACE ABB
Q = 1 12.61 (11.97, 13.24) 11.04 (9.58, 12.49) 7.96 (6.61, 9.32)
Q = 3 12.61 (11.97, 13.24) 12.54 (11.03, 14.05) 8.23 (6.61, 9.86)
Q = 5 12.61 (11.97, 13.24) 12.46 (10.80, 14.12) 8.92 (7.30, 10.55)
Q = 7 12.61 (11.97, 13.24) 12.55 (10.83, 14.27) 9.11 (7.52, 10.70)
ACM ABB
Q = 1 3.87 (3.50, 4.24) 2.26 (1.57, 2.94) 3.19 (2.33, 4.04)
Q = 3 3.87 (3.50, 4.24) 2.65 (1.99, 3.32) 3.43 (2.28, 4.58)
Q = 5 3.87 (3.50, 4.24) 2.72 (1.84, 3.60) 3.54 (2.61, 4.48)
Q = 7 3.87 (3.50, 4.24) 2.78 (2.00, 3.56) 3.39 (2.43, 4.35)
Table 12: Estimated 3-year risk ratio for MACE and ACM (95% confidence interval) among gli-
clazide second-line users
Outcome Method Sitagliptin vs. Gliclazide Pioglitazone vs. Gliclazide
MACE ABB
Q = 1 0.88 (0.77, 1.00)∗ 0.63 (0.56, 0.72)∗
Q = 3 0.97 (0.85, 1.11) 0.70 (0.60, 0.82)∗
Q = 5 0.96 (0.85, 1.08) 0.69 (0.59, 0.80)∗
Q = 7 0.99 (0.86, 1.15) 0.72 (0.63, 0.83)∗
ACM ABB
Q = 1 0.58 (0.47, 0.73)∗ 0.82 (0.64, 1.06)
Q = 3 0.70 (0.55, 0.87)∗ 0.89 (0.67, 1.18)
Q = 5 0.71 (0.54, 0.93)∗ 0.89 (0.67, 1.17)
Q = 7 0.72 (0.57, 0.91)∗ 0.87 (0.67, 1.15)
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